Centene Corporation (NYSE:CNC) Accelerates Margin Recovery Amid Strong Momentum

Centene’s operating cash generation and recent earnings surprise tighten the valuation gap while short-term technicals signal heightened probability of a near-term consolidation. The company shows improving margin dynamics alongside compressed multiples by traditional measures.

Recent News

April 6, 2026 — Centene announced a new executive leadership structure, creating two group-president roles and naming Daniel Finke and Michael Carson to senior posts. May 12, 2026 — Superior HealthPlan, a Centene company, awarded $100,000 in community grants and published other community-investment items; the company filed an 8-K on May 12 confirming executive officer appointments and formalizing the updated officer list.

Technical Analysis

ADX at 55.47 indicates a very strong trend; that strength raises the likelihood that directional shifts will produce meaningful short-term moves tied to fundamental news and earnings momentum.

DI+ at 41.0 with a decreasing trend contrasts with DI- showing a dip & reversal; the signals imply the prior bullish directional advantage has begun to weaken and directional pressure may shift toward sellers despite a historically stronger DI+ level.

MACD sits near 4.36 with a peak & reversal pattern and the MACD line below its 4.37 signal, indicating bearish momentum development rather than a bullish crossover; this momentum profile elevates short-term consolidation risk relative to continued breakout upside.

MRO at 13.29 with a peak & reversal indicates price currently trades above model target levels and carries an elevated probability of mean reversion; strength of the MRO read suggests the potential for a measurable pullback to re-synchronize price with valuation metrics.

RSI at 66.1 with an increasing trend signals sustained buying pressure approaching overbought territory, supporting the case for a short-term pause or pullback before any renewed leg higher.

Price sits above short-term averages — 12-day EMA increasing at $56.70 and 20-day average near $56.98 — and well above the 50- and 200-day averages; proximity to the upper Bollinger band and the Ichimoku Tenkan above Kijun corroborate recent upside, but momentum indicators suggest that continuation faces resistance from the noted bearish reversals.

 


Fundamental Analysis

Q1 results delivered an adjusted EPS of $3.37 versus an estimate of $2.13, a beat of $1.24 and an EPS surprise of 58.22%, reflecting stronger-than-expected profitability in the period. Net income totaled $1,541,000,000 and operating cash flow reached $4,366,000,000, underpinning robust cash generation.

Free cash flow of $4,166,000,000 implies a free cash flow yield of 21.95%, well above the industry peer mean, supporting a valuation discrepancy versus peers. Enterprise multiple stands at 4.53, consistent with materially compressed valuation versus typical peer multiples.

EBIT of $2,263,000,000 produces an EBIT margin of 4.53%, below the industry peer mean of 7.27% and marginally below the industry peer median of 4.69%; EBIT margin rose year-over-year by 10.24% while quarter-over-quarter moved -2.64% (QoQ), indicating recent quarter-level softness against a stronger YoY improvement.

Profitability and leverage metrics present mixed but serviceable credit fundamentals: return on equity at 7.19%, return on assets at 1.95%, debt-to-assets at 20.17%, and debt-to-EBITDA roughly 6.39x with an interest coverage ratio near 13.8x. Cash and short‑term investments total $23,741,000,000 against a market capitalization of $18,978,550,016, delivering sizable liquidity headroom.

Price multiples compress relative to peer averages: P/B at 0.89 sits below the industry peer mean of 1.97 and median of 1.56, and P/E near 11.45 remains markedly below the peer mean. Revenue showed a QoQ increase of 5.29% while YoY revenue change registered near -0.97%; operating margin dynamics trended modestly lower QoQ but improved YoY.

WMDST values the stock as under-valued. The valuation case rests on strong cash conversion, high free cash flow yield, low enterprise multiple, and a balance-sheet profile that supports execution of strategic initiatives while margins continue normalizing toward peer medians.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-03-31
REPORT DATE: 2026-04-28
NEXT REPORT DATE: 2026-07-28
CASH FLOW  Begin Period Cash Flow 18.0 B
 Operating Cash Flow 4.4 B
 Capital Expenditures -200.00 M
 Change In Working Capital 2.5 B
 Dividends Paid
 Cash Flow Delta 3.4 B
 End Period Cash Flow 21.4 B
 
INCOME STATEMENT REVENUE
 Total Revenue 49.9 B
 Forward Revenue 4.5 B
COSTS
 Cost Of Revenue 44.4 B
 Depreciation 134.0 M
 Depreciation and Amortization 300.0 M
 Research and Development
 Total Operating Expenses 48.1 B
PROFITABILITY
 Gross Profit 5.6 B
 EBITDA 2.6 B
 EBIT 2.3 B
 Operating Income 1.9 B
 Interest Income
 Interest Expense 164.0 M
 Net Interest Income -164.00 M
 Income Before Tax 2.1 B
 Tax Provision 560.0 M
 Tax Rate 26.7 %
 Net Income 1.5 B
 Net Income From Continuing Operations 1.5 B
EARNINGS
 EPS Estimate 2.13
 EPS Actual 3.37
 EPS Difference 1.24
 EPS Surprise 58.216 %
 Forward EPS 1.11
 
BALANCE SHEET ASSETS
 Total Assets 81.2 B
 Intangible Assets 15.2 B
 Net Tangible Assets 6.2 B
 Total Current Assets 45.0 B
 Cash and Short-Term Investments 23.7 B
 Cash 21.3 B
 Net Receivables 19.4 B
 Inventory
 Long-Term Investments 2.3 B
LIABILITIES
 Accounts Payable 16.8 B
 Short-Term Debt 63.0 M
 Total Current Liabilities 40.0 B
 Net Debt
 Total Debt 16.4 B
 Total Liabilities 59.6 B
EQUITY
 Total Equity 21.4 B
 Retained Earnings 10.2 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 43.57
 Shares Outstanding 493.771 M
 Revenue Per-Share 101.56
VALUATION
 Market Capitalization 19.0 B
 Enterprise Value 11.6 B
 Enterprise Multiple 4.529
Enterprise Multiple QoQ -126.166 %
Enterprise Multiple YoY -67.7 %
Enterprise Multiple IPRWA high: 159.017
median: 41.816
mean: 36.047
CNC: 4.529
low: -42.479
 EV/R 0.232
CAPITAL STRUCTURE
 Asset To Equity 3.788
 Asset To Liability 1.361
 Debt To Capital 0.433
 Debt To Assets 0.202
Debt To Assets QoQ -14.777 %
Debt To Assets YoY -4.176 %
Debt To Assets IPRWA high: 0.935
mean: 0.361
median: 0.292
CNC: 0.202
low: 0.006
 Debt To Equity 0.764
Debt To Equity QoQ -16.062 %
Debt To Equity YoY 16.425 %
Debt To Equity IPRWA high: 6.239
CNC: 0.764
median: 0.725
mean: -1.584
low: -7.908
PRICE-BASED VALUATION
 Price To Book (P/B) 0.886
Price To Book QoQ -12.786 %
Price To Book YoY -18.264 %
Price To Book IPRWA high: 10.639
mean: 1.966
median: 1.563
CNC: 0.886
low: -0.307
 Price To Earnings (P/E) 11.452
Price To Earnings QoQ -133.072 %
Price To Earnings YoY -45.381 %
Price To Earnings IPRWA high: 167.375
mean: 49.435
median: 41.682
CNC: 11.452
low: -165.821
 PE/G Ratio -0.03
 Price To Sales (P/S) 0.38
Price To Sales QoQ -6.753 %
Price To Sales YoY -41.438 %
Price To Sales IPRWA high: 9.603
mean: 2.61
median: 1.073
CNC: 0.38
low: 0.026
FORWARD MULTIPLES
Forward P/E 38.694
Forward PE/G -0.101
Forward P/S 4.737
EFFICIENCY OPERATIONAL
 Operating Leverage -600.746
ASSET & SALES
 Asset Turnover Ratio 0.633
Asset Turnover Ratio QoQ 1.019 %
Asset Turnover Ratio YoY 14.977 %
Asset Turnover Ratio IPRWA high: 1.21
CNC: 0.633
mean: 0.519
median: 0.397
low: 0.013
 Receivables Turnover 2.661
Receivables Turnover Ratio QoQ 10.297 %
Receivables Turnover Ratio YoY 20.312 %
Receivables Turnover Ratio IPRWA high: 10.101
median: 3.671
mean: 3.568
CNC: 2.661
low: 0.052
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 34.285
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 4.878
Cash Conversion Cycle Days QoQ
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 101.8
median: 19.637
mean: 16.481
CNC: 4.878
low: -62.922
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 10.102
 CapEx To Revenue -0.004
 CapEx To Depreciation -1.493
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 37.7 B
 Net Invested Capital 37.8 B
 Invested Capital 37.8 B
 Net Tangible Assets 6.2 B
 Net Working Capital 4.9 B
LIQUIDITY
 Cash Ratio 0.593
 Current Ratio 1.123
Current Ratio QoQ 2.122 %
Current Ratio YoY 1.067 %
Current Ratio IPRWA high: 3.361
CNC: 1.123
mean: 0.984
median: 0.854
low: 0.273
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 6.387
 Cost Of Debt 0.696 %
 Interest Coverage Ratio 13.799
Interest Coverage Ratio QoQ -268.596 %
Interest Coverage Ratio YoY 22.432 %
Interest Coverage Ratio IPRWA high: 35.836
CNC: 13.799
mean: 11.788
median: 7.359
low: -1.125
 Operating Cash Flow Ratio 0.093
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 29.407
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 5.77 %
 Revenue Growth 0.44 %
Revenue Growth QoQ 528.571 %
Revenue Growth YoY -96.912 %
Revenue Growth IPRWA high: 21.958 %
CNC: 0.44 %
mean: -2.248 %
median: -4.983 %
low: -9.495 %
 Earnings Growth -383.193 %
Earnings Growth QoQ 13.371 %
Earnings Growth YoY -245.978 %
Earnings Growth IPRWA high: 135.78 %
mean: 23.481 %
median: 1.648 %
low: -333.333 %
CNC: -383.193 %
MARGINS
 Gross Margin 11.128 %
Gross Margin QoQ 124.31 %
Gross Margin YoY -0.269 %
Gross Margin IPRWA high: 96.442 %
mean: 25.715 %
median: 15.558 %
CNC: 11.128 %
low: 4.2 %
 EBIT Margin 4.531 %
EBIT Margin QoQ -263.87 %
EBIT Margin YoY 10.243 %
EBIT Margin IPRWA high: 23.127 %
mean: 7.266 %
median: 4.692 %
CNC: 4.531 %
low: -12.88 %
 Return On Sales (ROS) 3.726 %
Return On Sales QoQ -250.363 %
Return On Sales YoY -9.343 %
Return On Sales IPRWA high: 22.401 %
mean: 7.429 %
median: 4.66 %
CNC: 3.726 %
low: -12.88 %
CASH FLOW
 Free Cash Flow (FCF) 4.2 B
 Free Cash Flow Yield 21.951 %
Free Cash Flow Yield QoQ 1886.516 %
Free Cash Flow Yield YoY 382.97 %
Free Cash Flow Yield IPRWA CNC: 21.951 %
high: 13.5 %
median: 3.132 %
mean: 2.888 %
low: -7.715 %
 Free Cash Growth 1759.821 %
Free Cash Growth QoQ -2287.825 %
Free Cash Growth YoY -716.27 %
Free Cash Growth IPRWA CNC: 1759.821 %
high: 298.093 %
mean: 17.614 %
median: 2.874 %
low: -455.219 %
 Free Cash To Net Income 2.703
 Cash Flow Margin 7.456 %
 Cash Flow To Earnings 2.417
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.952 %
Return On Assets QoQ -240.837 %
Return On Assets YoY 26.18 %
Return On Assets IPRWA high: 4.991 %
CNC: 1.952 %
median: 1.8 %
mean: 1.709 %
low: -4.166 %
 Return On Capital Employed (ROCE) 5.502 %
 Return On Equity (ROE) 0.072
Return On Equity QoQ -230.337 %
Return On Equity YoY 53.152 %
Return On Equity IPRWA high: 0.27
CNC: 0.072
median: 0.038
mean: -0.029
low: -0.261
 DuPont ROE 7.447 %
 Return On Invested Capital (ROIC) 4.39 %
Return On Invested Capital QoQ -267.302 %
Return On Invested Capital YoY 40.705 %
Return On Invested Capital IPRWA high: 7.1 %
CNC: 4.39 %
mean: 3.521 %
median: 2.946 %
low: -6.018 %

Six-Week Outlook

Near-term price action should favor consolidation with episodic volatility. Technical strength (high ADX and price above short-term EMAs) supports the persistence of a trend, but directional and momentum indicators (DI+ decreasing, DI- dip & reversal, MACD peak & reversal, MRO positive and peaking, rising RSI) raise the probability of a corrective leg before continuation. Fundamentals — a sizable EPS beat, strong operating cash flow, high free cash flow yield, and compressed valuation metrics — provide a constructive longer-dated bias; however, expect the next several weeks to price in margin cadence and any company commentary from upcoming filings or guidance updates. Close monitoring of momentum indicators and cash-flow signals will best indicate whether consolidation resolves toward renewed upside or deeper mean reversion.

About Centene Corporation

Centene Corporation (NYSE:CNC) delivers comprehensive healthcare services, primarily targeting under-insured and uninsured populations across the United States. Established in 1984 and based in St. Louis, Missouri, Centene develops a wide array of health plans through its Medicaid, Medicare, and Commercial segments. The Medicaid segment offers expanded health plans, children’s health insurance programs, and long-term services. In the Medicare segment, Centene addresses the needs of seniors with special needs plans, Medicare supplements, and prescription drug plans. The Commercial segment provides marketplace insurance products for individuals and businesses, ensuring extensive access to healthcare services. Centene actively participates in government healthcare contracts, including the TRICARE program for military families, highlighting its dedication to diverse communities. The company also manages clinical healthcare services, pharmacies, and provides dental and speech therapy, promoting a holistic healthcare approach. By collaborating with primary and specialty care physicians, hospitals, and ancillary providers, Centene aims to deliver personalized, high-quality care to millions of Americans, emphasizing innovation and community well-being.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.